Area of research
Genetics · Pathology and Forensic Medicine
Research interest
Research interests include Chronic Lymphocytic Leukemia Research, Lymphoma Diagnosis and Treatment, CAR-T cell therapy research, and Immunodeficiency and Autoimmune Disorders.
Glofitamab in Relapsed/Refractory Mantle Cell Lymphoma: Results From a Phase I/II Study
Glofitamab monotherapy induces high complete response rates and manageable safety in Chinese patients with heavily pretreated relapsed or refractory diffuse large B-cell lymphoma
Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Glofitamab Monotherapy Induces High Complete Response Rates in Patients with Heavily Pretreated Relapsed or Refractory Mantle Cell Lymphoma
Glofitamab Monotherapy Demonstrates High Complete Response Rates and Manageable Safety in Chinese Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma and ≥2 Prior Therapies
Glofitamab Step-up Dosing Induces High Response Rates in Patients (pts) with Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL), Most of Whom Had Failed Prior Bruton's Tyrosine Kinase Inhibitor (BTKi) Therapy
Glofitamab As Monotherapy and in Combination with Obinutuzumab Induces High Complete Response Rates in Patients (pts) with Multiple Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
Population Pharmacokinetics and Exposure–Response Analyses for Venetoclax in Combination with R-CHOP in Relapsed/Refractory and Previously Untreated Patients with Diffuse Large B Cell Lymphoma
Integrative prognostic models predict long-term survival after immunochemotherapy in chronic lymphocytic leukemia patients
Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study
A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma
Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax
Glofitamab Step-up Dosing Induces High Response Rates in Patients with Hard-to-Treat Refractory or Relapsed Non-Hodgkin Lymphoma
Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions
Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables
Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia
Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study
MYC Pathway Activation Is Frequently Observed in Treatment-Naive CLL and Defines a Subgroup with Particular Benefit from the Addition of Rituximab to Chemotherapy
Venetoclax and obinutuzumab in chronic lymphocytic leukemia
Venetoclax Plus Rituximab Is Superior to Bendamustine Plus Rituximab in Patients with Relapsed/ Refractory Chronic Lymphocytic Leukemia - Results from Pre-Planned Interim Analysis of the Randomized Phase 3 Murano Study
Results of the Safety Run-in Phase of CLL14 (BO25323): A Prospective, Open-Label, Multicenter Randomized Phase III Trial to Compare the Efficacy and Safety of Obinutuzumab and Venetoclax (GDC-0199/ABT-199) with Obinutuzumab and Chlorambucil in Patients with Previously Untreated CLL and Coexisting Medical Conditions
Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions